
Dec 3 (Reuters) - Lockheed Martin said on Wednesday it has opened a hypersonics system integration lab at its Huntsville campus as it pushes to develop next-generation weapons.
Hypersonic weapons, which can travel at more than five times the speed of sound and evade traditional defenses, are at the centre of an arms race between the United States and China.
Lockheed's 17,000-square-foot facility will include advanced test equipment, simulation tools and an integration environment.
It is part of a larger capital program that now totals roughly $529 million and includes 719,000 square feet of facilities under construction or planned, the company said.
"Hypersonic weapons are reshaping the future of military defense by delivering unmatched speed and maneuverability that outpace traditional threats," said Holly Molmer, program management director for Lockheed Martin
In October, defense start-up Castelion said it won contracts to integrate its Blackbeard hypersonic strike weapon with current U.S. Army systems.
(Reporting by Aishwarya Jain in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
The 25 Most Notable Style Crossroads in History - 2
Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe - 3
Bird flu poses risk of pandemic worse than COVID, France's Institut Pasteur says - 4
Step by step instructions to Analyze Senior Insurance Contracts Really. - 5
Figure out How to Plan for Your Web-based Degree monetarily
Fetterman says he's back home after a fall put the Pennsylvania senator in the hospital
Get Cooking: 15 Speedy and Heavenly Recipes for Occupied Individuals
7 Powerful Methods for forestalling Telephone Overheating: Keep Your Gadget Cool
Beating Scholastic Difficulties: Understudy Examples of overcoming adversity
A definitive Manual for the 5 Off-road Bicycles Available
The most effective method to Pick the Right Material Organization: Fundamental Tips
Famous Versatile Brands: Your Decision
Damaged Shenzhou-20 spacecraft to return to Earth uncrewed for inspection
Roche breast cancer pill cuts risk of disease recurrence by 30% in trial













